CHU Edouard Herriot Report issue

Academic/Hospital Phase 2 Phase 3 Phase 4
Founded: Lyon France (1933)

Organization Overview

First Clinical Trial
2004
NCT00287846
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

CHU Edouard Herriot - Lyon - France | Groupement Hospitalier Edouard Herriot | Groupement Hospitalier Edouard Herriot,69437 Lyon Cedex 03 | HOPITAL EDOUARD HERRIOT | Hôpital Edouard Herriot | Hopital Edouard Herriot - Lyon | Service d'imagerie, pavillon B Hôpital Edouard Herriot

Active Ingredients

Drugs in Phase 4 Trials (1)

polyethylene glycol (1 trial)

Drugs in Phase 3 Trials (4)

cyclosporine (sandimmune) (1 trial)

ethiodized oil (ethiodol) (1 trial)

idursulfase (elaprase) (1 trial)

testosterone (delatestryl) (1 trial)

Drugs in Phase 2 Trials (1)

imatinib (gleevec) (1 trial)

Drugs in Other Trials (1)

landiolol (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Digestive System Diseases (Phase 4)

Erectile Dysfunction (Phase 3)

Fibroma (Phase 2)

Fibromatosis, Aggressive (Phase 2)

Gastrointestinal Diseases (Phase 4)

Heart Arrest (Phase 3)

Hypogonadism (Phase 3)

Liver Neoplasms (Phase 3)

Mucopolysaccharidoses (Phase 3)

Mucopolysaccharidosis II (Phase 3)

Out-of-Hospital Cardiac Arrest (Phase 3)

Syndrome (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 7
  • # of Trial APIs: 7